-
公开(公告)号：KR101096417B1
公开(公告)日：2011-12-21
申请号：KR1020090097150
申请日：2009-10-13
Applicant: 숙명여자대학교산학협력단
Abstract: 본 발명은 아사론(asarone)을 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학 조성물, 아사론을 유효성분으로 함유하는 C/EBPα(CCAAT/enhancer binding protein-α) 및 PPARγ(peroxisome proliferator activated receptor-γ) 발현 저해제 및 아사론을 유효성분으로 함유하는 당뇨병 예방 또는 개선용 건강기능식품에 관한 것이다.
C/EBPα, PPARγ, 아디포넥틴, 아사론, 호르몬 민감성 리파아제-
2.发明公开
公开(公告)号：KR1020110040028A
公开(公告)日：2011-04-20
申请号：KR1020090097150
申请日：2009-10-13
Applicant: 숙명여자대학교산학협력단
Abstract: PURPOSE: A pharmaceutical composition containing asarone is provided to prevent or relieve diabetes. CONSTITUTION: A pharmaceutical composition for preventing or treating diabetes contains 0.01-50 weight% of asarone as an active ingredient. The pharmaceutical composition further contains a carrier, excipient, and diluent. The pharmaceutical composition is manufactured in the form of powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, external use formulation, suppository, and sterilized injection solution. An inhibitor of C/EBP alpha and PPAR gamma contains asarone as an active ingredient. A health food for preventing or relieving diabetes contains asarone as an active ingredient.
Abstract translation: 目的：提供含有asarone的药物组合物，以预防或缓解糖尿病。 构成：用于预防或治疗糖尿病的药物组合物含有0.01-50重量％的asarone作为活性成分。 药物组合物还含有载体，赋形剂和稀释剂。 药物组合物以粉末，颗粒，片剂，胶囊，悬浮液，乳剂，糖浆，气雾剂，外用制剂，栓剂和灭菌注射液的形式制备。 C /EBPα和PPARγ抑制剂含有asarone作为活性成分。 用于预防或缓解糖尿病的保健食品含有asarone作为活性成分。
-
3.发明授权인간 씨티알피1 유전자의 에스아이알엔에이, 및 이를포함하는 고혈압 및 심혈관계 질환 치료용 약학조성물 有权人CTRP1基因的siRNA，以及包含用于治疗高血压和心血管疾病的siRNA的药物组合物
公开(公告)号：KR100976170B1
公开(公告)日：2010-08-16
申请号：KR1020070128640
申请日：2007-12-12
Applicant: 숙명여자대학교산학협력단
Abstract: 본 발명은 인간 CTRP1 단백질의 생성을 억제하는 인간 CTRP1 유전자의 siRNA 및 이를 포함하는 고혈압 또는 심혈관질환 치료용 약학조성물을 제공한다. 본 발명은 또한 인간 CTRP1 유전자 또는 인간 CTRP1 단백질을 포함하는 고혈압 또는 심혈관질환 치료제 스크리닝 조성물 및 이를 이용한 스크리닝 방법을 제공한다. 추가로, 본 발명은 인간 CTRP1 단백질에 대한 항체를 포함하는 고혈압 또는 심혈관질환 진단 조성물 및 이를 포함하는 고혈압 또는 심혈관질환 진단용 키트를 제공한다.
CTRP1, 알도스테론, 고혈압, 심혈관질환-
公开(公告)号：KR1020100086713A
公开(公告)日：2010-08-02
申请号：KR1020090006090
申请日：2009-01-23
Applicant: 숙명여자대학교산학협력단
IPC: C07D277/36 , C07D277/32 , A61P3/10 , A61P9/12
Abstract: PURPOSE: A novel rhodanine derivative which activates PPAR gamma is provided to prevent or treat PPAR-mediated diseases. CONSTITUTION: A beta-rhodanine derivative is denoted by chemical formula 1. A pharmaceutical composition for preventing and treating PPAR gamma-mediated diseases contains beta-carboxyethyl-rhodanine derivative or pharmaceutically acceptable salt as an active ingredient. The PPAR gamma-mediated diseases are diabetes, hypertension, artery scleroma, cardiovascular disease or metabolic disorder.
Abstract translation: 目的：提供激活PPARγ的新型罗丹明衍生物，以预防或治疗PPAR介导的疾病。 构成：β-绕丹宁衍生物由化学式1表示。用于预防和治疗PPARγ介导的疾病的药物组合物含有β-羧乙基 - 绕丹宁衍生物或药学上可接受的盐作为活性成分。 PPARγ介导的疾病是糖尿病，高血压，动脉硬化，心血管疾病或代谢紊乱。
-
Patent Agency Ranking
-
6.发明公开인간 씨티알피1 유전자의 에스아이알엔에이, 및 이를포함하는 고혈압 및 심혈관계 질환 치료용 약학조성물 有权人类CTRP1基因的SIRNA和包含SIRNA用于治疗高血压和心脏血管疾病的药物组合物
公开(公告)号：KR1020090061727A
公开(公告)日：2009-06-17
申请号：KR1020070128640
申请日：2007-12-12
Applicant: 숙명여자대학교산학협력단
Abstract: A pharmaceutical compound for treating hypertension or cardiovascular diseases, which contains siRNA(single interfering RNA) of human CTRP1(complement C1q TNF related protein 1) is provided to inhibit generation of aldosterone by suppressing the human CTRP1 generation. A siRNA of human CTRP1 gene which suppresses the generation of human CTRP1 comprises polynucleotide pair of the sequence numbers 3(SEQ ID NO:3) and 4, or 5 and 6. A pharmaceutical composition for treating hypertension or cardiovascular diseases comprises the siRNA of human CTRP1 gene as an inhibition material of human CTRP1 generation. The pharmaceutical composition comprises a human CTRP1 antibody as an inhibitor of human CTRP1 function. The human CTRP1 antibody is produced by a hybridoma cell line E21H7. A composition for screening the drug for hypertension or cardiovascular diseases comprises the human CTRP1 gene or protein.
Abstract translation: 提供含有人CTRP1（补体C1q TNF相关蛋白1）的siRNA（单干扰RNA）的高血压或心血管疾病的药物化合物，通过抑制人类CTRP1的产生来抑制醛固酮的产生。 抑制人CTRP1产生的人CTRP1基因的siRNA包含序列号3（SEQ ID NO：3）和4或5和6的多核苷酸对。用于治疗高血压或心血管疾病的药物组合物包含人的siRNA CTRP1基因作为人类CTRP1生成的抑制物质。 药物组合物包含人CTRP1抗体作为人CTRP1功能的抑制剂。 人类CTRP1抗体由杂交瘤细胞系E21H7产生。 用于筛选高血压或心血管疾病药物的组合物包括人类CTRP1基因或蛋白质。
-
公开(公告)号：KR1020140020437A
公开(公告)日：2014-02-19
申请号：KR1020120086772
申请日：2012-08-08
Applicant: 숙명여자대학교산학협력단
Inventor： 양영
IPC: C12N5/10 , C12N15/85 , A01K67/027 , G01N33/15
Abstract: The present invention relates to a CTRP1-overexpressed transgenic mouse as a research model for the research of high blood pressure and the development of therapeutic agents. The CTRP1-overexpressed transgenic mouse of the present invention can be effectively applied to the research of occurrence mechanism and the development of therapeutic agents for high blood pressure and various diseases caused by the high blood pressure.
Abstract translation: 本发明涉及一种CTRP1过表达的转基因小鼠，作为研究高血压和治疗药物发展的研究模式。 本发明的CTRP1过表达的转基因小鼠可以有效地应用于高血压引起的高血压和各种疾病的发生机制和治疗剂的研究。
-
公开(公告)号：KR101095734B1
公开(公告)日：2011-12-21
申请号：KR1020090006090
申请日：2009-01-23
Applicant: 숙명여자대학교산학협력단
IPC: C07D277/36 , C07D277/32 , A61P3/10 , A61P9/12
Abstract: 본 발명은 사람 퍼옥시좀 증식제 활성화 수용체인 PPARγ를 활성화시키는 신규한 로다닌 유도체 화합물에 관한 것이다. 본 발명에서는 PPARγ 활성제로 작용하는 베타-카복시에틸-로다닌 유도체 또는 약학적으로 허용되는 이의 염이 제공된다. 본 발명에 따른 베타-카복시에틸-로다닌 유도체는 PPARγ를 조절하는 작용을 가짐으로써 PPAR에 의해 매개되는 당뇨병, 고혈압, 동맥경화증, 심혈관계 질환, 대사성질환 등에 대하여 예방, 개선 및 치료효과를 나타낼 수 있다.
PPARγ, PPARγ활성제, 로다닌 유도체, 베타-카복시에틸-로다닌 유도체, PPARγ 매개 질환, 당뇨병, 대사성질환-
公开(公告)号：KR1020070109347A
公开(公告)日：2007-11-15
申请号：KR1020060042197
申请日：2006-05-11
Applicant: 숙명여자대학교산학협력단
Abstract: A hybridoma cell is provided to secret a monoclonal antibody capable of specifically recognizing human CTRP1(C1q-TNF related protein-1) and immunoprecipitating it. A monoclonal antibody is provided to detect the CTRP1 protein economically and conveniently and be widely used for diagnosing, preventing and treating obesity or diabetes. A hybridoma cell E21H7 produces mouse monoclonal antibodies binding to human CTRP1 and is deposited as a deposition no. KCTC 10944BP. A method for producing the hybridoma cell E21H7 comprises the steps of: (a) immunizing mouse using a fusion protein of human CTRP1; (b) fusing a spleen cell of the immunized mouse into myeloma cell and then culturing it; and (c) selecting hybridoma cells producing monoclonal antibodies specific to the human CTRP1 from the fused hybridoma cells. An IgG2a type monoclonal antibody specific to human CTRP1 is prepared by the hybridoma cell E21H7.
Abstract translation: 提供了一种杂交瘤细胞来保护能够特异性识别人类CTRP1（C1q-TNF相关蛋白-1）并免疫沉淀的单克隆抗体。 提供单克隆抗体经济地和方便地检测CTRP1蛋白，被广泛用于诊断，预防和治疗肥胖或糖尿病。 杂交瘤细胞E21H7产生与人CTRP1结合的小鼠单克隆抗体，并作为沉积物沉积。 KCTC 10944BP。 制备杂交瘤细胞E21H7的方法包括以下步骤：（a）使用人CTRP1的融合蛋白免疫小鼠; （b）将免疫小鼠的脾细胞融合入骨髓瘤细胞，然后培养; 和（c）从融合的杂交瘤细胞中选择产生对人CTRP1特异性的单克隆抗体的杂交瘤细胞。 通过杂交瘤细胞E21H7制备对人CTRP1特异性的IgG2a型单克隆抗体。
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.02 seconds)
